A STUDY TO DECREASE QUANTITY OF ROPIVACAINE WITH DEXMEDETOMIDINE IN ULTRASOUND GUIDED SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK IN FOREARM AND HAND SURGERIES
Phase 2
- Conditions
- Health Condition 1: S529- Unspecified fracture of forearm
- Registration Number
- CTRI/2022/07/044034
- Lead Sponsor
- DR PAYAL GEHLOT
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA GRADE 1 AND 2
SURGERY TYPE- ELECTIVE FOREARM AND HAND SURGERIES
Exclusion Criteria
PATIENTS WHO REFUSE TO BE PART OF THE SYUDY
SIGNIFICANT COAGULOPATHIES
HISTORY OF BRACHIAL PLEXUS INJURY
ALLERGY TO STUDY DRUG
PSYCHIATRIC HISTORY
INFECTION AT THE SITE OF INJECTION
PREGNANT PATIENTS
DIAPHRAGMATIC PARALYSIS
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TO DETERMINE MINIMUM VOLUME OF 0.5% ROPIVACAINE WITH DEXMEDETOMIDINE IN USG GUIDED SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK REQUIRED TO GET SURGICAL ANAESTHESIA IN FOREARM AND HAND SURGERYTimepoint: WITHIN 30 MINUTES OF ADMINISTRATION OF DRUG
- Secondary Outcome Measures
Name Time Method ASSESSMENT OF BLOCK IN TERMS OF ONSET AND DURATION OF SENSORY AND MOTOR BLOCK <br/ ><br>MONITORING OF HAEMODYNAMIC PARAMETERSTimepoint: 6 HOURS <br/ ><br>;TIME OF FIRST RESCUE ANALGESIC ADMINISTRATION <br/ ><br>ADVERSE EFFECTSTimepoint: APPROX 24 HOURS